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.2012.05.0Abstract Several methods and techniques are potentially useful for the preparation of micropar-
ticles in the ﬁeld of controlled drug delivery. The type and the size of the microparticles, the entrap-
ment, release characteristics and stability of drug in microparticles in the formulations are
dependent on the method used. One of the most common methods of preparing microparticles is
the single emulsion technique. Poorly soluble, lipophilic drugs are successfully retained within the
microparticles prepared by this method. However, the encapsulation of highly water soluble com-
pounds including protein and peptides presents formidable challenges to the researchers. The suc-
cessful encapsulation of such compounds requires high drug loading in the microparticles,
prevention of protein and peptide degradation by the encapsulation method involved and predict-
able release, both rate and extent, of the drug compound from the microparticles. The above men-
tioned problems can be overcome by using the double emulsion technique, alternatively called as
multiple emulsion technique. Aiming to achieve this various techniques have been examined to pre-
pare stable formulations utilizing w/o/w, s/o/w, w/o/o, and s/o/o type double emulsion methods.
This article reviews the current state of the art in double emulsion based technologies for the prep-
aration of microparticles including the investigation of various classes of substances that are phar-
maceutically and biopharmaceutically active.
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The goal of any drug delivery system is to deliver a therapeutic
amount of drug to the proper site in the body and then main-
tain the therapeutic concentration over a desired period of
time. Various conventional drug delivery systems are being
used widely to achieve systemic action of drugs. However, in
some cases conventional drug delivery manifests toxic side ef-
fects. Following, a relatively short period at the therapeutic le-
vel, drug concentration eventually drops until re-administered.
Novel drug delivery systems have overcome the above men-
tioned limitations of conventional drug delivery systems.
Many efforts in developing novel drug delivery system have
been focused on controlled release and sustained release
dosage forms. There are various approaches in delivering atherapeutic substance to the target site in a sustained or
controlled release fashion. One such approach is using micro-
particles as carrier for drugs. Microparticles offer greater effec-
tiveness, lower toxicity and better stability than conventional
dosage forms (Naha et al., 2008). Microparticulate drug deliv-
ery systems are used to prolong the delivery of the drug, to im-
prove bioavailability, to enhance stability and, to target drug
to speciﬁc site (Barakat and Ahmad, 2008). Microparticles
have been prepared by a judicious blend of polymers with dif-
ferent coat core ratios utilizing various methods such as o/w
single emulsion solvent evaporation (Dai et al., 2011; Khaled
et al., 2010; Yang and Gao, 2010), spray drying (Ramtoola
et al., 2011; Yan et al., 2010; Zhang et al., 2010; Khan and
Kumar, 2011), ionotropic gelation (Li et al., 2010;
Chakraborty et al., 2010; Ma and Liu, 2010; Sriamornsak
Figure 1 Preparation of microparticles by the double emulsion solvent evaporation method.
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Celik and Akbuga, 2007; Bayomi, 2004), air suspension, and
polymerization (Farook et al., 2008; Lu and Zhang, 2006; Chen
et al., 2011; He et al., 2011; Hao et al., 2011; Shi et al., 2011).
The o/w single emulsion solvent evaporation method is the
widely used one among various microencapsulation tech-
niques. Water insoluble drugs are successfully retained within
microparticles prepared by this method. However, the method
is not efﬁcient for the entrapment of hydrophilic drugs because
of rapid dissolution of the compounds into the aqueous con-
tinuous phase. The problem of efﬁcient encapsulation of
hydrophilic drugs can be overcome by using the double emul-
sion technique. Many types of pharmaceuticals and biophar-
maceuticals with different physico-chemical properties have
been formulated into microparticles by double emulsion meth-
od (Chang et al., 2011; Lu et al., 2011; Karal-Ylmaz et al.,
2011; Oh et al., 2011; Liu et al., 2010; Dalmoro et al., 2010;
Blatsios et al., 2010). Many review articles have been published
on controlled release microparticulate drug delivery system
using single emulsion technique. However, no comprehensive
review has yet been published on preparation of microparticles
using double emulsion technique. This article after extensive
survey of literatures presents a report on the advances in the
double emulsion technique and the characteristics of micropar-
ticles produced by this method. This review also includes the
investigation of various classes of pharmaceutical and biophar-
maceutical active components used for preparing microparti-
cles by double emulsion technique.
2. Limitations of the single emulsion method for the preparation
of microparticles
The main limitation of this method is its limited ability to
encapsulate water soluble drugs for their partitioning into
the aqueous phase of the emulsion (Bodmeier and McGinity,
1987a,b). A further effect of partitioning is the accumulation
of drug crystals on the surface of microparticles, which pro-
duces a burst release of the drug upon administration. The par-
titioning effect of the drug can be reduced by chemicallymodifying it to a lipophilic prodrug prior to its incorporation
into the organic phase (Seki et al., 1990). Otherwise modiﬁca-
tion of the continuous phase of the emulsion to reduce leakage
of the drug from the oily droplets can be employed. Several
researchers have therefore suggested replacement of the con-
tinuous phase with a less hydrophilic one, as in the case of
the non-aqueous emulsion of o/o type (Sturesson et al., 1993;
Bodmeier and McGinity, 1987c; Spenlehauer et al., 1988).
However, the mineral oil or vegetable oil used as an external
oil phase in o/o emulsion is difﬁcult to collect or to remove
from the resulting microparticles.3. Advantages of the double emulsion method for the preparation
of microparticles
The double emulsion method has been considered better since
the method is relatively simple, convenient in controlling pro-
cess parameters, and has the ability to produce with simple
instrument. The process can efﬁciently encapsulate highly
water soluble compounds including proteins and peptides.4. Preparation of microparticles using double emulsion technique
4.1. W/O/W double emulsion solvent evaporation technique
In the water in oil in water (w/o/w) double emulsions, the
internal and external aqueous phases are separated by an oil
layer. For their formation and stability, at least two surfac-
tants, one having a low HLB to form the primary water in
oil (w/o) emulsion and the other of higher HLB to achieve sec-
ondary emulsiﬁcation are required to emulsify water in oil
emulsion into water. These emulsion (w/o/w) systems being
less viscous are excellent candidates for controlled release of
hydrophilic drugs due to the existence of a middle oil layer that
acts as a liquid membrane.
In water/oil/water double emulsion solvent evaporation
method, an aqueous solution or suspension of the drug (inter-
nal aqueous phase, W1) is emulsiﬁed in a solution of polymer
128 T.K. Giri et al.in organic solvent. The resulting primary emulsion (W1/O) is
then dispersed in a second aqueous phase (external aqueous
phase, W2) containing suitable emulsiﬁer(s) to form double
emulsion (W1/O/W2). Removal of the volatile organic solvent
leads to the formation of solid microparticles (Fig. 1). The so-
lid microparticles are separated by ﬁltration or centrifugation,
washed several times in order to eliminate the residual emulsi-
ﬁer and dried under vacuum or freeze-dried. The volatile or-
ganic solvent used in the preparation of the microparticles
by the double emulsion solvent evaporation method should
be of low boiling point to facilitate the removal of residual sol-
vent. Various solvents that can be used for the preparation of
microparticles are acetonitrile, ethyl acetate, chloroform, and
benzene and methylene chloride. Uchida et al. (1995) prepared
ovalbumin loaded poly(lactide-co-glycolide) (PLGA) micro-
particles by a w/o/w emulsion solvent evaporation technique
using NaCl for protection of the internal aqueous droplets.
PLGA is a copolymer of lactic acid and glycolic acid. It has
been most widely used since their degradation rate and
mechanical properties can be precisely controlled by varying
the lactic acid/glycolic acid ratio and by altering the molecular
weight of the polymers. Author tried to improve the loading
efﬁciency and release of protein of the PLGA microspheres.
Using a smaller volume of an internal aqueous phase resulted
in a comparatively high loading efﬁciency than a large volume
of the internal aqueous phase. The addition of NaCl into the
external aqueous phase also improved ovalbumin loading efﬁ-
ciency. Microscopic examination suggested that in the pres-
ence of NaCl in the external aqueous phase, the internal
aqueous droplets were stable and were not expelled during
the second emulsiﬁcation. Molecular weight of PLGA is a fac-
tor for release characteristics of the prepared microparticles of
ovalbumin. The rate of release of ovalbumin from microparti-
cles decreased with an increase in molecular weight of PLGA.
Graves et al. (2004) investigated the effect of blending of low
molecular weight (Mw) and high molecular weight (Mw)
PLGA on the characteristics of microparticles prepared by
double emulsion solvent evaporation technique. The drug
entrapment efﬁciency increased signiﬁcantly when high Mw
PLGA (RG 506) was mixed with low Mw PLGA (RG 502)
at a ratio of 1:7. However, this formulation also showed signif-
icantly high burst release which implies that a major portion of
the encapsulated drug was deposited near the surface. The
water soluble peptide, pBC 264, was encapsulated in PLGA
microparticles using double emulsion solvent evaporation
method (Blanco-Prieto et al., 1997). The encapsulation efﬁ-
ciency of pBC 264 in microparticles was very low (<20%)
when the inner aqueous phase did not contain any stabilizing
agent. However, the encapsulation efﬁciency was improved
to about 41% by the addition of ovalbumin used as stabilizer
of the inner emulsion. An additional and signiﬁcant improve-
ment of the encapsulation efﬁciency (90%) was observed when
pH of the internal aqueous phase was basic (pH 8 correspond-
ing to the optimal solubility of the pBC 264) and when the pH
of the external aqueous phase was acid (pH 2.5 corresponding
to a lower solubility of pBC 264). In vitro release experiments
showed that more than 60% of the peptide released after
10 min. However, the extent of release of the peptide slowed
down when the microparticles were prepared with the higher
Mw copolymer.
Ovalbumin loaded PLGA microparticles were prepared
using w/o/w double emulsion solvent evaporation method byvarying the external aqueous phase surfactant (Coombes
et al., 1998). PVP stabilized microparticles exhibited higher
protein loading, about 8.2%w/w, compared to PVA stabilized
microparticles, about 4%w/w. The use of PVP instead of PVA
to prepare microparticles also resulted in reduction in the ini-
tial burst release of ovalbumin. The former polymer resulted
the sustained protein release over 28 days with an increase in
the protein delivery capacity from 35 to 45 lg/mg particles.
The PVP is more soluble in organic polymer solution than
PVA. Therefore, PVA stabilizer molecules can be expected to
be conﬁned to the surface of the microparticles formed in
the w/o/w technique. However, extensive diffusion of PVP
molecules into the dispersed droplets of polymer solution can
be envisaged. The diffusion of PVP(stabilizer) molecules from
the external aqueous phase increased the viscosity of the drop-
lets of polymer solution and consequently improved the pro-
tein loading and delivery characteristics. The effect of
molecular weight and morphological structure of the copoly-
mer on size, yield, degradation rate, bovine serum albumin
(BSA) loading efﬁciency and BSA release proﬁle of the micro-
particles prepared by w/o/w double emulsion method were
studied by (Porjazoska et al., 2004). The microparticles pre-
pared from poly(DL-lactide–coglycolide) showed biphasic pro-
ﬁle for BSA release. However, microparticles prepared from
poly(L-lactide–coglycolide) showed triphasic proﬁle for BSA
release. Blanco-Prieto et al. (2002) prepared gentamicin loaded
PLGA microparticles using a double emulsion solvent evapo-
ration technique. The encapsulation efﬁciency was found to
vary from 34% to 90% depending on the formulation. More-
over, encapsulation efﬁciency depended on the pH values of
the internal aqueous phase and the highest value was achieved
when the internal aqueous phase was maintained at pH 6. The-
ophylline loaded enteric coated microparticles were prepared
using a w/o/w solvent evaporation technique for targeted oral
drug delivery (Dalmoro et al., 2010). Initially, the cellulose ace-
tate phthalate (CAP) was used as a pH sensitive polymer for
the preparation of microparticles. The desired release pattern
was achieved but not the encapsulation efﬁciency. Then, the
CAP was replaced by a novel synthesized pH sensitive poly(-
methyl methacrylate acrylic acid) copolymer. It has been ob-
served that the encapsulation efﬁciency was directly related
to the amount of emulsion stabilizer but inversely related to
the stirring speed. By increasing the concentration of emulsion
stabilizer (PVA) and by decreasing the stirring speed, a high
stable double emulsion was obtained which increased the
encapsulation efﬁciency. The use of polymethylmethacrylate
(PMMA) polymers for controlled delivery of diclofenac so-
dium was investigated by Pal et al. (2011). PMMA coated
microparticles were prepared by a modiﬁed w/o/w emulsion
solvent evaporation method using sodium alginate as a matrix
material in the internal aqueous phase. The microparticles
were spherical with diameters ranging from 213.45 to
308.60 lm and entrapment efﬁciency from 28.71% to
72.16% was reported. Drug entrapment efﬁciency of the ma-
trix microparticles was found to be considerably higher than
that of non-matrix microparticles and increased with increase
in the concentration of the matrix material. Release of the drug
from all the microparticles appeared to be biphasic releasing
less amount of drug in simulated gastric ﬂuid and higher
amount of drug in simulated intestinal ﬂuid. Moreover, the re-
lease of the drug from most of the microparticles was observed
to follow non-ﬁckian model. Increase in the concentration of
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Figure 2 Scheme of the preparation procedure for drug loaded microparticles by the double emulsion solvent evaporation method.
130 T.K. Giri et al.matrix material (sodium alginate) improved the viscosity of
internal aqueous phase minimizing the leaching of the drug
into external aqueous phase thus the drug entrapment efﬁ-
ciency increased consequently.
Cohen et al. (1991) prepared PLGAmicrospheres containing
ﬂuorescin isothiocyanate labeled BSA and horseradish peroxi-
dase using a w/o/w double emulsion solvent evaporation meth-
od. The prepared microcapsules were spherical and more than
90% encapsulation efﬁciencies were reported. Unencapsulated
horseradish peroxidase lost 80% of its activity in solution at
37 C in a few days. However, the encapsulated enzyme retained
more than 55% of its activity after 21 days incubation at 37 C.
Insufﬁcient solvent removal is likely to cause microparti-
cles’ aggregation with decrease in the drug entrapment efﬁ-
ciency due to unsatisfactory speed of solvent removal from
microparticles (Yamamoto et al., 1990; Takechi et al., 1998).
The above mentioned problem was solved by Takechi et al.
(2002) by developing a method to increase the speed of solvent
removal from microparticles prepared from w/o/w double
emulsion method. The drug entrapment efﬁciency in micropar-
ticles also improved markedly. The rate of solvent removal
from the microparticles can be controlled by the temperature
of the microsphere dispersion (Yang et al., 2000a,b). The char-
acteristics of drug loaded microparticles prepared by the w/o/w
solvent evaporation method are listed in Table 1.
4.2. W/O/W double emulsion solvent extraction technique
In this technique, the solvent can be removed from the micro-
particles through extraction of the solvent present in the inter-
nal phase. This can be achieved by the addition of w/o/w
emulsion to a third solution, which is a non solvent of the poly-
mer but miscible with both water and the organic solvent. Un-
der these conditions the solvent contained in the polymer
droplets is extracted into the aqueous medium. In this method,
an aqueous solution or suspension of the drug is emulsiﬁed in a
solution of polymer in organic solvent. The resulting primary
emulsion is then dispersed in a second aqueous phase contain-
ing suitable emulsiﬁer to form double emulsion. Removal of
the solvent by extraction leads to the formation of solid micro-
particles (Fig. 2).
Ruan et al. (2002) prepared human serum albumin loaded
microparticles by the w/o/w solvent extraction method. They
investigated the effects of different materials used for the prep-
aration of microparticles: (a) PLGA (PLA-PGA) and PELA
(PLA-PEG-PLA) as the polymers, (b) dichloromethane, ethyl
acetate and acetone as the solvents, (c) PEG and D-a tocophe-
ryl polyethylene glycol 1000 succinate (vitamin E TPGS) as
additives. The encapsulation efﬁciency value of human serumalbumin in PELA microparticles was about 10% higher than
that in PLGA microparticles, may be due to improved stability
of w/o emulsion by PELA. Dichloromethane mixed with 70%
acetone or 100% ethyl acetate resulted in 69.09% and 65.33%
of encapsulation efﬁciency, respectively. The encapsulation
efﬁciency of using either low (2%) or high concentration
(10%) of these two additives (PEG and vitamin E TPGS)
was around 25% lower than that obtained without the use
of additives. The displacement of the drug molecules from
w/o emulsion interface by the surfactants (PEG or vitamin E
TPGS) decreased the amount of drug located within the w/o
emulsion resulting in lower entrapment efﬁciency. More than
90% of the encapsulated protein was released from PELA
microparticles within 13 days. Higher PEG concentration
(10%) resulted in more porous structure and slightly faster
protein release. Recombinant human interleukin-2 loaded
PLGA microparticles were prepared using modiﬁed w/o/w
double emulsion solvent extraction method for pulmonary
administration (Devrim et al., 2011). The encapsulation efﬁ-
ciency of drug was 99.22%. The in vitro release study exhibited
a biphasic pattern, characterized by a fast release phase at ﬁrst
day, followed by a slower release on the subsequent days. Li
et al. (1999) prepared leptospira interrogans antigens loaded
PELA microparticles by solvent extraction method based on
the formation of double w/o/w emulsion. By using a small vol-
ume of internal aqueous phase and intermediate volumes of
organic phase and external aqueous phase, the microparticles
with a size of 1–2 lm and encapsulation efﬁciency of 70–
80% were achieved. The antigen release proﬁles from PELA
microparticles consist of a small burst release followed by a
gradual release phase.
A novel technique was used in double emulsion solvent
extraction for the preparation of microparticles (Ereitas
et al., 2005). In this technique, a ﬂow through ultrasonic cell
was used for the preparation of primary emulsion and a static
micromixer was used for the preparation of double emulsion.
The microparticles with a size range of 15–40 lm and 70%
drug encapsulation efﬁciency were achieved. PELA micropar-
ticles containing Hepatitis B surface antigen were prepared by
a solvent extraction method based on the formation of a dou-
ble w/o/w emulsion (Zhou et al., 2004). The PELA micropar-
ticles displayed the highest encapsulation efﬁciency (80%) and
improved stability of antigen molecules in the PELA micropar-
ticles during the preparation process.
4.3. S/O/W double emulsion technique
Using solids a double emulsion of solid in oil in water(s/o/w)
can be prepared, in which the internal solid phase and external
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pharmaceuticals or biopharmaceuticals are dispersed in the
polymer solution to form a primary emulsion. Then the disper-
sion is introduced into a large volume of aqueous solution con-
taining emulsifying agent, such as PVA or PEG. The most
commonly used encapsulation method for the preparation of
microparticles is the w/o/w double emulsion technique. How-
ever, protein inactivation and aggregation are largely caused
by protein adsorption on to the oil/water interface which is
formed when the aqueous protein solution is emulsiﬁed under
high shear with the organic solvent of choice (Crotts and Park,
1998; Weert Van De et al., 2000; Sah, 1999). The s/o/w tech-
nique has gained recognition since it improves protein stability
during encapsulation because the ﬁrst w/o emulsion step is
avoided (Castellanos et al., 2001; Putney and burke, 1998).
Morita and his coworkers (Morita et al., 2000) prepared pro-
tein loaded biodegradable microparticles by a novel s/o/w
emulsion method using polyethylene glycol as a protein micr-
onization adjuvant. They prepared monolithic type micropar-
ticles by a simple s/o/w emulsion method and reservoir type
microparticles by the polymer alloys method. By this technol-
ogy protein can be efﬁciently encapsulated into microparticles
without any loss of activity. The protein release kinetics could
be suitably modiﬁed by adjusting the loading amounts of PEG.
If PEG is increased the entrapment of protein decreases and
release would be faster. The reason for lower entrapment is
partly because a large amount of PEG might enhance the leak-
age of protein particles into aqueous phase. The ﬁrst release
kinetics could be due to distribution of PEG in the polymer
layer that enhances the water permeation, resulting in the
prompt formation of aqueous channels through the shell. A
novel stabilization strategy using polyethylene glycol as stabi-
lizing excipient as well as emulsifying agent was developed by
(Castellanos et al., 2003). They prepared PLGA microparticles
for encapsulation of c-chymotrypsin and horseradish peroxide
by a s/o/w technique. The use of PEG as stabilizing excipient
and emulsiﬁer allowed encapsulation of c-chymotrypsin in
PLGA microparticles without causing aggregation and loss
in the enzyme activity. Moreover, aggregation and inactivation
of model proteins during encapsulation was prevented with
increasing amounts of PEG co-encapsulated in the microparti-
cles. Surface active PEG prevented the inactivation of the en-
zyme by protecting it upon exposure to two hydrophobic
denaturing substances: Solvent (methylene chloride) and poly-
mer (PLGA). Takada and his coworkers (Takada et al., 2003)
prepared biodegradable microparticles by a s/o/w emulsion
solvent evaporation technique using lyophilized protein micro-
particles for sustained release of recombinant human growth
hormone (rhGH). High entrapment of rhGH in microparticles
was achieved by incorporating rhGH powder of smaller parti-
cle size. It was observed that the incorporation of zinc oxide
into microparticles resulted in higher serum levels than with
those prepared without zinc oxide, after subcutaneous injec-
tion into rats. The microparticles prepared by using PLGA
with molecular weight of 12600 demonstrated almost zero-or-
der release proﬁle resulting in constant serum rhGH levels for
2 weeks. Addition of zinc oxide into microparticles resulted in
higher serum levels than with those prepared without zinc
oxide, suggesting the stabilizing effect of zinc oxide after sub-
cutaneous injection into rats. Similarly, c-chymotrypsin has
been encapsulated in PLGA microparticles using the s/o/w
encapsulation technique (Castellanos et al., 2002). Threedifferent c-chymotrypsin formulations were employed to pre-
pare microparticles: (a) lyophilized without excipient, (b) co-
lyophilized with trehalose, (c) co-lyophilized with PEG at a
1:4 weight ratio (protein: excipient). The highest encapsulation
efﬁciency (72%) was achieved with PEG as the excipient, while
protein formulation with trehalose resulted in the lowest
encapsulation efﬁciency (27%).
4.4. S/O/O double emulsion technique
Similarly, in the solid in oil in oil (s/o/o) double emulsions, the
internal solid phase and external oil phase are separated by an
oil phase. The s/o/o emulsion can be prepared by dispersing
solid particles in an organic solvent, e.g. methylene chloride,
and then mixed with a polymer solution. Alternatively the dis-
persion of solids in organic solvent can be coated with a suit-
able polymer using a coacervation technique. Carrasquillo and
his coworkers (Carrasquillo et al., 2001) prepared BSA loaded
PLGA microparticles by a non-aqueous s/o/o methodology. In
this methodology, powder formulations of BSA obtained by
spray-freeze drying were ﬁrst suspended in methylene chloride
containing PLGA followed by coacervation by adding silicon
oil and microsphere hardening in heptanes. The release of
BSA from PLGA microparticles was governed by an asymp-
totic proﬁle in which > 80% of the protein was released rap-
idly within only 2 days. However, blending of PLGA with
poloxamer had a dramatic effect on the in vitro release of
BSA, speciﬁcally an increase in the release duration. Polox-
amer is a triblock copolymer composed of polyoxyethylene
and polyoxypropylene. The author suggested that the micro-
sphere diameter was signiﬁcantly increased by the presence
of poloxamer in the o/o procedure. Leach and his coworkers
(Leach et al., 2005) developed a method in which the coacer-
vate droplets are introduced into a spinning cottonseed oil ﬁlm
at a controllable ﬂow rate. So that the shear generated by the
spinning ﬁlm separates the droplets to produce uniform micro-
particles. The resultant microparticles showed higher encapsu-
lation efﬁciency and lower initial burst release compared with
microparticles produced by a conventional emulsiﬁcation tech-
nique. Moreover, the optimized formulation showed slow re-
lease to 2.14% in 18 days and gradual release to 63% for
next 55 days.
4.5. W/O/O double emulsion technique
In the water in oil in oil(w/o/o) double emulsions, the internal
aqueous phase and external oil phase are separated by an oil
phase. In the w/o/o method, water soluble compounds are ﬁrst
dissolved in the aqueous phase which is emulsiﬁed in an oil to
form a stable emulsion. This primary emulsion is then dis-
persed in a solution of polymer in organic solvent to form a
w/o/o emulsion. Water soluble compounds cannot diffuse into
the processing medium since the oil is outer processing
medium.
The total protein encapsulation efﬁciency is high in the
microparticles produced by w/o/o emulsiﬁcation technique
since oil is the outer processing medium and protein cannot
diffuse into the processing medium. PLGA microparticles were
prepared by using a w/o/o double emulsiﬁcation evaporation
technique for the long term delivery of angiogenic inhibitors
for the treatment of cancer (Wu et al., 2009). The mean particle
132 T.K. Giri et al.size of endostatin microparticles was about 25 lm and the
encapsulation efﬁciency was 100%. The in vitro release study
showed that the microparticles allowed the sustained release
of biologically active endostatin for 30 days. Moreover,
in vitro studies on rats, endostatin microparticles produced a
sustained release process in which the steady-state concentra-
tion was reached from 5th day to 27th day with the steady-
state levels of endostatin between 174.8 and 351.3 mg/ml,
respectively. Ciombor and his coworkers (Ciombor et al.,
2006) prepared BSA loaded PLGA microparticles using a
modiﬁed w/o/o emulsion solvent removal method. They stud-
ied various factors including composition of the suspension
medium and the relative amounts of aqueous phase containing
protein to polymer solution. High yields of microparticles were
achieved by using silicon oil containing a mixture of methylene
chloride and silicon oil, as a suspension medium, instead of
pure silicon oil. When polymer solution and continuous phase
at a ratio of 1:0.5 was used, a cake like polymer matrix of irreg-
ular shape was produced. However, at ratios of 1:1 to 1:9
spherical microparticles were produced.
5. Categories of pharmaceuticals and biopharmaceuticals used
for encapsulation into microparticles prepared by double
emulsion method
Encapsulation of certain pharmaceuticals and biopharmaceu-
ticals in microparticles are reviewed with examples from the
literature.
5.1. Pharmaceuticals
5.1.1. Anticancer drugs
5.1.1.1. Cisplastin. Cisplastin is a divalent inorganic water solu-
ble platinum containing complex widely used as anticancer
drugs. It is very effective inmetastatic testicular and ovarian car-
cinoma. The usual intravenous dose of cisplastin is 20 mg/m2
per day for ﬁve days. Matsumoto et al. (1997) prepared cispla-
stin loaded multireservoir type microparticles by s/o/w double
emulsion method using PLA and PLGA as polymers. The
PLGA-PLA biphasic polymeric solution containing dispersed
drug powders was emulsiﬁed, and then solidiﬁed by the solvent
evaporation method. The resultant microparticles showed al-
most 100% encapsulation efﬁciency. The in vitro release study
indicated that the release of cisplastin continued for 45 days
without initial burst. Cisplastin loaded microparticles were pre-
pared from D,L-lactic acid stereo copolymers and D,L-lactic acid/
glycolic acid copolymers using a s/o/w double emulsion solvent
evaporation process (Spenlehauer et al., 1988). It has been
observed that the drug release depends on the amount of
entrapped drug and polymer molecular weights. Moreover,
the drug release mechanism was predominantly diffusional by
either polymer matrices or dissolution in channels depending
upon cisplastin crystal distribution in microparticles. Similarly,
cisplastin loaded PLGA microparticles were prepared by s/o/w
double emulsion method (Spenlehauer et al., 1986) for chemo-
embolization. The resultant microparticles showed high encap-
sulation efﬁciencies with little or no burst release.
5.1.1.2. 5-Fluorouracil. 5-Fluorouracil is a pyrimidine whose
analogs have varied applications like antineoplastic, antifungal
and antipsoriatic agents. It is very effective in breast, colon,
urinary bladder and liver carcinoma. The usual oral dose is1 g on alternate days (6 days) then 1 g weekly. It has a half life
of 10–20 min. 5-Fluorouracil loaded PLA microparticles were
prepared by using double emulsion method for hepatic artery
embolism treatment (Xin-Xia et al., 2010). The resultant
microparticles showed 63.34% drug encapsulation efﬁciency
and released the drug in a controlled manner. Chandy et al.
(2000) developed chitosan coated PLA/PLGA injectable
microparticles containing 5-ﬂuorouracil using w/o/w double
emulsion method for cerebral tumors. It has been observed
that the drug release was initially much higher (25%), followed
by a constant slow release proﬁle for a 30 days period of study.
In another study, 5-ﬂuorouracil and antisense oligonucleotide
were co-entrapped in single microparticles formulations and
also entrapped individually using PLGA polymer by w/o/w
double emulsion method (Hussain et al., 2002). Both types
of formulation exhibited suitable entrapment and drug release
over 35 days.
5.1.1.3. Doxorubicin. Doxorubicin is an antitumour antibiotic
which is effective in many solid tumors. The recommended dose
of doxorubicin is 60–75 mg/m2, administered as a single rapid
intravenous infusion that is repeated after 21 days. Jiang et al.
(2011) prepared PLGA microparticles loaded with doxorubin,
PEGylated TNF-related apoptosis inducing ligand (PEG-
TRAIL), andwith doxorubicin plus PEG-TRAILusing aw/o/w
double emulsion solvent extraction method for effective tumor
combination therapy. The encapsulation efﬁciency of 69.4%
for doxorubicin and 87.7% for PEG-TRAIL was observed. It
has also been observed that the PLGA microparticles loaded
with low amounts of doxorubicin, PEG-TRAIL, or dual agent
resulted in 14.8%, 30.2%, and 63.6% reductions in human colon
cancer tumor volume and 20.4%, 14.2%, and 67.7% reductions
in human prostate cancer tumor volume at 5–35 days.
5.1.1.4. Epirubicin. Epirubicin is an anthracycline antibiotic
used for chemotherapy. It has half life of 30–40 h. The recom-
mended dose of epirubicin is 100–120 mg/m2 by intravenous
infusion every 3–4 weeks. Zhou and his coworkers (Zhou
et al., 2006) studied the effectiveness of treating hepatocellular
carcinoma (HCC) in mice with locally administered epirubicin
loaded PLA microparticles. They prepared microparticles by
double emulsion solvent evaporation technique. The micropar-
ticles signiﬁcantly prolonged the survival time of mice.
5.1.2. Anti-inﬂammatory drugs
5.1.2.1. Aceclofenac. Aceclofenac is an aryl-acetic acid deriva-
tive widely used as an analgesic. The usual oral dose is 100 mg
twice daily. It has half life of 3–4 h. Aceclofenac loaded micro-
particles were prepared by an o/w/o double emulsion method
(Nagda et al., 2008). The entrapment efﬁciency was in the
range of 32–47%. Aceclofenac release from these microparti-
cles was slow and extended over longer periods of time with
ﬁckian diffusion control. In another study, aceclofenac loaded
bioadhesive microparticles were prepared by o/w/o double
emulsion solvent evaporation method using polycarbophil as
bioadhesive polymer (Nagda et al., 2009). The prepared poly-
carbophil microparticles showed reasonable drug entrapment,
suitable size and relatively slow release of the drug.
5.1.2.2. Acetaminophen. Acetaminophen is a mild analgesic-
antipyretic, with little anti-inﬂammatory properties. It has a
biological half life of about 2 h. The usual adult dose is 0.5–
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(2005) prepared acetaminophen loaded PLA microparticles by
three emulsion solvent evaporation methods: o/w emulsion
method, o/w co-solvent method and w/o/w double emulsion
method. The encapsulation efﬁciency in the w/o/w emulsion
method was three times more compared to the o/w emulsion
method. Moreover, the microparticles prepared by the w/o/w
double emulsion method showed good controlled release
characteristics.
5.1.2.3. Diclofenac sodium. Diclofenac sodium, a non steroidal
anti-inﬂammatory drug, is widely used in rheumatoid arthritis,
severe osteoarthritis and in ankylosing spondylitis. Its biolog-
ical half life is 1–2 h and is administered 2–3 times a day. A no-
vel poloxamer coated three-ply-walled microparticles were
prepared based on the technique of multiple emulsion forma-
tion polymer at the interface followed by rigidization of the
wall on evaporation of solvent for controlled delivery of dic-
lofenac sodium (Bhatnagar et al., 1995). The microparticles
were prepared by w/o/w double emulsion solvent evaporation
method using ethyl cellulose as hydrophobic polymer. The
resultant microparticles showed sustained release of the con-
tained diclofenac. Similarly, Pal and his coworkers (Pal
et al., 2011) prepared diclofenac sodium loaded polymethyl-
methacrylate microparticles by a modiﬁed w/o/w emulsion sol-
vent evaporation method using sodium alginate as a matrix
material in the internal aqueous phase. The resultant matrix
microparticles appeared to be suitable for releasing lesser
amounts of diclofenac sodium in simulated gastric ﬂuids and
providing extended release in simulated intestinal ﬂuid.
5.1.2.4. Ketoprofen. Ketoprofen is a propionic acid derivative
widely used as analgesic and antipyretic. It has a half life of
about 2–2.5 h and is completely absorbed from the gut. The
recommended daily dose is 100–150 mg per day in divided
doses. Pavanetto et al. (1996) prepared ketoprofen loaded
chitosan microparticles by the o/w/o double emulsion method.
The double emulsion method produced well formed micropar-
ticles with high yield. The lowest theoretical drug/chitosan ra-
tio showed the highest drug encapsulation efﬁciency.
5.1.3. Antibiotics
5.1.3.1. Gentamicin. Gentamicin is the most important amino-
glycoside antibiotics and is used widely for the treatment of
serious infections. The plasma half life is 2 h, and the minimum
inhibitory concentration against pseudomonas should be be-
tween 6 and 10 lg/ml. Biodegradable PLA and/or PLA/PEG
copolymer disk implants containing gentamicin sulfate were
obtained by compression of microparticles prepared by a
w/o/w double emulsion process for local treatment of bone
infection (Huang and Chung, 2001). The PLA/PEG implant
released the antibiotic faster and had a larger inhibitory zone
based on the Boner-Kirby experiments used to assess the
inhibitory activity of antimicrobial devices. It has been ob-
served that the biodegradable PLA/PEG gentamicin delivery
system had a potential for prophylaxis of post-operative
injection.
5.1.3.2. Erythromycin. Erythromycin is a macrolide antibiotic
and is administered as an alternative to the penicillin-allergic
patient. The half life is 1.5–3 h. Only 20% of the drug is
excreted by the kidneys; the remainder is metabolized bydemethylation or appears in the bile, where it is highly concen-
trated. The usual dose for erythromycin stearate is between
250 and 500 mg every 6 hours. Erythromycin loaded gelatin
microparticles were prepared using a w/o/w double emulsion
solvent evaporation method for lung targeting (Fan et al.,
2009). The drug loading and encapsulation efﬁciency of micro-
particles were 13.56% and 55.82%, respectively. The in vitro
release study indicated an initial burst release and following
a sustained release with a cumulative release of 80% at 4 h.
The in vivo study in rabbits indicated the concentration of
erythromycin in lung was 15.92 times higher than that in plas-
ma and the drug targeting index of microparticles in lung was
6.65 times as compared to erythromycin lactobionate.5.1.3.3. Cephalexin. Cephalexin is a ﬁrst generation cephalo-
sporin antibiotic. It is used for ﬁrst line treatment for cellulitis.
It has a half life of about 0.5–1.2 h. The oral dose is 0.25–1 g
repeated 6–8 hourly. Chaisri et al. (2009) prepared cephalexin
loaded PLGA microparticles using a w/o/w emulsion technol-
ogy for the treatment of dairy mastitis. It has been observed
that stirring during emulsiﬁcation and a change in both the
internal and external phase of the emulsion, inﬂuenced the size
and the drug entrapment efﬁciency of the microparticles. The
stirring rate of 8000–10,000 rpm gave high yield (>90%)
microparticles with a desirable size and high drug entrapment
efﬁciency.
5.1.3.4. Capreomycin. Capreomycin is a polypeptide antibiotic
and widely used for the treatment of tuberculosis. The half life
is about 3–6 h. The usual dose is 1 g intramuscularly daily.
Giovagnoli et al. (2007) prepared capreomycin sulfate loaded
microparticles using a simple emulsion solvent evaporation
method for pulmonary delivery. PLGA microparticles were
prepared using a w/o/w double emulsion solvent evaporation
method. The homogenization method and the type of emulsi-
ﬁer employed strongly affected the microparticles size distribu-
tion. The double emulsion method allowed the preparation of
microparticles having suitable characteristics of such respira-
bility requirements.
5.1.3.5. Norﬂoxacin. Norﬂoxacin is a synthetic chemothera-
peutic antibacterial agent occasionally used to treat common
as well as complicated urinary tract infections. It has a half life
of about 3–4 h. The usual oral dose is 800 mg per day.
Norﬂoxacin is a ﬂuoroquinoline derivative widely used as an
antibiotic. Sindhuri and Purushotaman (2011) prepared
norﬂoxacin loaded microparticles using various polymers like
carbopol 934, sodium carboxymethyl cellulose by w/o/w dou-
ble emulsion solvent evaporation technique. The prepared
microparticles showed good ﬂow properties with spherical
shape and surface morphology. Moreover, microparticles
showed sustained release of the drug from the formulation
for a period of 12 h.
5.1.4. Steroidal drugs
5.1.4.1. Budesonide. Budesonide is a glucocorticoid and widely
used for the treatment of asthma. The half life is about 2–3.6 h.
The usual dose is 200–400 lg twice or thrice daily by inhala-
tion in asthma. Budesonide is a corticosteroid widely used
for the treatment of asthma. Budesonide loaded porous PLGA
microparticles were prepared by a w/o/w double emulsion
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et al., 2011). The drug loading efﬁciency in the microparticles
was about 60%, and drug was released from the microparticles
in a sustained manner for 24 h in vitro. It has been observed
that the budesonide loaded microparticles signiﬁcantly reduced
bronchial hyper-responsiveness of asthmatic mice.
5.1.4.2. Triamcinolone acetonide. Triamcinolone acetonide is a
synthetic corticosteroid used to treat various skin conditions
and to relieve the discomfort of mouth sores. It has a half life
of 88 minutes. The usual oral dose is 4–32 mg per day. Triam-
cinolone acetate loaded microparticles were prepared by a sin-
gle or double emulsion solvent evaporation method (Blatsios
et al., 2010). Then the microparticles compressed into mini-
tablets. In vitro studies revealed a sustained release of drug
over several hours. Triamcinolone acetate accumulated in the
vitreous and aqueous humor of Cadaver rabbit eyes following
scleral administration of the mini-tablets.
5.1.5. Anti HIV agents
5.1.5.1. Zidovudine. Zidovudine is an antiretroviral drug used
for the treatment of HIV/AIDS. It has a half life of 0.5–3 h.
The usual oral dose is 200 mg every 4 h continuously. Zidovu-
dine encapsulated ethyl cellulose microparticles were prepared
by w/o/o double emulsion solvent diffusion method (Das and
Rao, 2006). The resultant microparticles showed 32–55%
entrapment efﬁciency with free ﬂowing properties. The drug
release was found to be diffusion controlled.
5.1.5.2. Stavudine. Stavudine is a nucleoside analog and used in
HIV infection. The usual oral dose is 30 mg every 12 h before
one hour food. Sahoo and his coworkers (Sahoo et al., 2007)
prepared stavudine loaded microparticles by w/o/o double
emulsion solvent diffusion method using ethyl cellulose and a
mixture of ethyl cellulose and polyvinyl pyrrolidone. The pre-
pared microparticles were free ﬂowing and spherical in shape
with 41–65% of drug entrapment efﬁciency. The release of
stavudine was inﬂuenced by the drug to polymer ratio, size
of the microparticles and polymer combination.
5.1.6. Other drugs
5.1.6.1. Pseudoephedrine HCl. Pseudoephedrine HCl is a sym-
pathomimetic drug. It has been orally administered as a decon-
gestant of upper respiratory tract, nose and eustachian tubes.
The half life is about 4.3–8 h. The usual oral dose is 240 mg
per day. Pseudoephedrine HCl loaded carnauba wax micro-
particles were prepared by a w/o/w double emulsion melt dis-
persion technique (Bodmeier et al., 1992). The prepared
microparticles showed above 80% drug encapsulation efﬁ-
ciency. The drug loading depended on the rate of cooling
and the volume of the internal aqueous phase.
5.1.6.2. Sodium fusidate. Sodium fusidate is a bacteriostatic
antibiotic. It has a half life of 5–6 h. The recommended oral dose
is 250 mg twice daily. Cevher et al. (2007) prepared PLGA
microparticles containing sodium fusidate using a w/o/w double
emulsion solvent evaporation method with varying polymer to
drug ratios. The resultant microparticles showed 19.8–34.3%
encapsulation efﬁciency. The in vitro and in vivo studies indi-
cated that the implanted sodium fusidate loaded microparticles
were found to be effective for the treatment of chronic osteomy-
elitis in an animal experimental model.5.1.6.3. Amifostine. Amifostine is a cytoprotective adjuvant
used in cancer chemotherapy. It has a half life of 8 min. The
usual intravenous dose is 910 mg/m2 once daily. Lu et al.
(2011) prepared amifostine loaded PLGA microparticles using
a modiﬁed double emulsion solvent evaporation technique.
They also investigated its irradiation protective effect to mouse
through oral administration. The prepared microparticles were
spherical in shape with a mean diameter of 2.8 lm. In vitro re-
lease study showed a relatively large burst effect (50%) over the
ﬁrst 6 h, followed by a slower release phase, which sustained
with 80% amifostine released in 48 h and almost 100% release
till 6 days. In vivo study revealed that amifostine microparticles
were more irradiation shielding to mouse than those of free
amifostine under the same oral administration route.
5.1.6.4. Theophylline. Theophylline is a xanthine derivative
widely used as an effective bronchodilator in the management
of asthma. It has a half life of 5–8 h. The usual intravenous
dose is 2.5–5 mg of anhydrous drug per kg body weight over
a period of 20 min. Jelvehgari et al. (2011) encapsulated the-
ophylline loaded poly(e-caprolactone) nanoparticles in ethyl
cellulose microparticles by using w/o/w double emulsion sol-
vent diffusion/evaporation method. The prepared drug loaded
composite microparticles showed minimum burst effect, satis-
factory release and mean particle size of 17.696 lm.
5.2. Biopharmaceuticals
5.2.1. Bovine serum albumin (BSA)
Bovine serum albumin is a serum albumin protein derived from
cows. It is often used as standard protein concentration stan-
dard. BSA loaded PLGA microparticles were prepared using
a modiﬁed w/o/o double emulsion phase separation method
(Zhang et al., 2005). Microparticles with high yield (>80%)
and entrapment efﬁciency (>90%) were produced using petro-
leum ether containing 5% (w/v) span 80 as coacervating agent.
A biphasic release behavior was observed for the microparticles
prepared by this method. Pistel and Kissel (2000) investigated
the effects of salt addition on the microencapsulation of BSA
using w/o/w double emulsion solvent evaporation technique.
For the preparation of microparticles poly(L-lactide) was used
as performed polymer. Modiﬁcation of the external water
phase by adding salts produced microparticles with high encap-
sulation efﬁciency and excellent microparticles characteristics.
Similarly, BSA was encapsulated in polyethylene glycol micro-
particles using a double emulsion technique (Thummala et al.,
2003). It was observed that the production parameters signiﬁ-
cantly affected protein release rates.
5.2.2. Lysozyme
Lysozyme is glycoside hydrolase that damages the bacterial
cell walls. The usual oral dose of lysozyme chloride is 60–
270 mg thrice a day. Lysozyme loaded PLA microparticles
were prepared by combining Shirasu porous glass (SPG) mem-
brane emulsiﬁcation technique and w/o/w double emulsion
solvent evaporation method (Liu et al., 2005). The drug encap-
sulation efﬁciency of microparticles prepared by SPG mem-
brane emulsiﬁcation technique was much higher than that
prepared by stirring method. The drug encapsulation efﬁciency
was affected by PLA molecular weight, additive type and
amount in the internal water phase, emulsiﬁer type and
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in the external water phase. In another study, the effect of
emulsiﬁcation of lysozyme solutions with methylene chloride
on protein recovery and structural integrity was investigated
(Weert Van de et al., 2000). The PLGA microparticles were
prepared by w/o/w double emulsion method. Excipients com-
peting for the water/organic solvent interface, such as BSA and
partially polyvinyl alcohol signiﬁcantly improved lysozyme
recovery to >95%. Perez et al. (2002) prepared lysozyme
loaded PLGA microparticles using a w/o/w double emulsion
technique. It has been observed that the protein aggregation
and inactivation were minimized by judiciously selecting excip-
ients efﬁcient in stabilizing lysozyme against the major stress
factors of w/o/w encapsulation.
5.2.3. a-Chymotrypsin
a-Chymotrypsin is a digestive enzyme that can perform prote-
olysis. a-Chymotrypsin preferentially cleaves peptide amide
bonds. a-Chymotrypsin loaded PLGA microparticles were
prepared by using a w/o/w double emulsion technique for its
stabilization toward the major stress factors during the encap-
sulation procedure (Perez-Rodriguez et al., 2003). It has been
observed that co-dissolving the protein with maltose and poly-
ethylene glycol in the ﬁrst aqueous phase reduced interface in-
duced protein aggregation and inactivation. Employing these
excipients during encapsulation led to a reduction in a-chymo-
trypsin inactivation (10%) and aggregation (12%).
5.2.4. Insulin
Insulin is poorly absorbed via the intestinalmembrane because of
extensive proteolytic degradation by intestinal enzymes and suf-
fers from insufﬁcient membrane permeability due to high molec-
ular weight and low lipophilicity. Insulin loaded PLA-PEG
microparticles were prepared using aw/o/w double emulsion sol-
vent evaporation technique for controlled parenteral drug deliv-
ery (Sheshala et al., 2009). The prepared microparticles were
spherical in structure with a mean particle size of 3.07 lm and
entrapment efﬁciency of 42.74%. The in vitro insulin release pro-
ﬁle was characterized by a bimodal behavior with an initial burst
release followed by slower and continuous release. Kang and
Singh, 2005 prepared insulin loaded PLGA microparticles by
w/o/w and s/o/w double emulsion method for providing basal
insulin level for an extended period of time. It has been observed
that the insulin loaded PLGA microparticles controlled in vitro
absorption of insulin tomaintain the basal insulin level for a long
period and the delivery system was biocompatible. In another
study, insulin loaded PLGA microparticles were prepared by a
novel s/o/w solvent evaporation process (Bao et al., 2006). Mod-
iﬁed s/o/w process encapsulatedmore than 90% (w/w) insulin in
themicroparticles and the initial burst wasmuch less thanmicro-
particles made by a w/o/w process.
5.2.5. Leuprolide
Leuprolide is a potent agonist of leutinizing hormone-releasing
hormone currently used for the treatment of prostatic cancer,
endometriosis and precocious puberty. The usual intramuscu-
lar dose is 1 mg daily. Leuprolide loaded PLA microparticles
were prepared using a s/o/w double emulsion method (Woo
et al., 2001). The prepared microparticles were spherical in
shape with a mean diameter of 52 lm and 13.4% encapsula-
tion efﬁciency. Ten percent of the peptide released within24 h followed by a linear release for 150 days. Serum leupro-
lide levels increased immediately after administration to
45.6 ng/ml due to the initial burst release from the microparti-
cles. Then the levels fall to 4.3 ng/ml at day 15 followed by a
plateau level around 2 ng/ml or less over 120 days.
5.2.6. Hepatitis B surface antigen
Hepatitis B surface antigen is the most frequently used screen-
ing agent for HBV infection. It is the ﬁrst detectable viral anti-
gen to appear during infection. The usual adult dose is 1 ml
intramuscularly and child dose is 0.5 ml intramuscularly. Hep-
atitis B surface antigen loaded PELA microparticles were pre-
pared quickly by a novel method using w/o/w emulsion solvent
extraction and premix membrane emulsiﬁcation (Wei et al.,
2008). It has been observed that the distribution pattern of
PEG segment of polymers played an important role on the
properties of microparticles. Diblock copolymer PLA-mPEG
yielded a more stable interfacial layer at the interface of oil
and water phase compared to triblock copolymer PLA-PEG-
PLA and resulting in high encapsulation efﬁciency.
5.2.7. Recombinant human erythropoietin (rhEPO)
Recombinant human erythropoietin is widely used for the
treatment of anemia associated with renal insufﬁciency and
cancer. The administration of rhEPO is 300–600 IU/kg 3–4
times per week. Morlock et al. (1997) encapsulated rhEPO, a
stimulating factor of red blood cell production, into PLGA
microparticles using a w/o/w double emulsion technique. A
distinct reduction of the formation of rhEPO aggregates was
achieved by using excipients such as cyclodextrin, arginine,
or BSA. Accelerated stability study demonstrated no change
in drug content, release behavior and aggregate proﬁle over
56 days at 20 C, 8 C or room temperature.
5.2.8. Tetanus toxoid
Tetanus toxoid is a sterile dispersion of toxoid in isotonic so-
dium chloride solution. It protects infants against the risks
of tetanus neonatorum by immunizing pregnant mothers.
The dose consists of 0.5 ml at least 4 weeks apart, at
18 months, 5 yrs, 10 yrs, 16 yrs and then every 10 yrs. Katare
and Panda (2006) investigated the effect of serum albumin, su-
crose and sodium bicarbonate on surface morphology, entrap-
ment efﬁciency, in vitro release and in vivo performance of TT
loaded PLA microparticles prepared by w/o/w double emul-
sion method. Maximum entrapment efﬁciency of TT was
achieved when serum albumin, sucrose and sodium bicarbon-
ate were used in internal aqueous phase and sucrose was used
in the external aqueous phase. The optimized microparticles
showed burst release of immunoreactive antigens (>40% in
early period) and elicited high and sustained anti-TT antibody
titers from single point intramuscular immunization.
5.2.9. Leutinizing hormone releasing hormone (LHRH)
antagonist
Leutinizing hormone releasing hormone antagonist produces a
competitive blockade of LHRH receptors and causes an imme-
diate inhibition of the release of gonadotropins and sex ste-
roids. Du et al. (2006) prepared LHRH antagonist loaded
microparticles to treat prostate cancer. The microparticles
were prepared by three methods: (a) double emulsion solvent
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extraction/evaporation technique, and (c) s/o/o double emul-
sion method. The prepared microparticles were smooth and
with round surfaces. The drug encapsulation efﬁciency of
microparticles was inﬂuenced by LA/GA ratio of PLGA, salt
concentrations, solvent mixture and preparation methods. In
another study, LHRH antagonist, orntide acetate was success-
fully incorporated into PLA and PLGA microparticles pre-
pared by w/o/w double emulsion method (Kostanski et al.,
2000). Peptide binding to microparticles was dependent upon
pH and was markedly higher in phosphate buffer pH 7.4 than
in acetate buffer pH 4.0. In vitro release of peptide in phos-
phate buffer varied from 0.5% to 26%/24 h but due to sub-
stantial binding of the peptide to the polymeric matrix the
long term release in phosphate buffer could not be determined.
5.2.10. Staphylokinase variant K35R (DGR)
Staphylokinase variant K35R is a recombinant mutant of
Staphylococcus aureus enzyme in which lysine (K) at position
35 is replaced by arginine (R). It is used to treat thrombotic
disorders. He et al. (2006) prepared DGR loaded PLGA
microparticles using a w/o/w double emulsion solvent extrac-
tion technique. It has been observed that the DGR encapsula-
tion efﬁciency was signiﬁcantly increased from 7.1% to 78%,
when 2% polyvinyl alcohol was coencapsulated and 2.5%
NaCl was added to the external water phase. In vitro release
study revealed that DGR was released from PLGA micropar-
ticles in a sustained manner over 15 days.
5.2.11. Brain derived neurotrophic factor (BDNF)
Brain derived neurotrophic factor, a secreted protein, is en-
coded by the BDNF (member of neurotrophin) gene in human
brain. BDNF helps to stimulate and control neurogenesis.
Bertram et al. (2010) investigated the role of chemistry of the
polymer played in loading and delivery of BDNF via micro-
particles. It was observed that a triblock polymer of PLGA,
PLL, and PEG led to the delivery of BDNF for periods of time
greater than 60 days. The released protein was active up to
65 days based on PCl2 cell morphology.
5.2.12. Interferon-alpha 26 (IFN-a26)
Interferon-alpha 26 has been widely used to treat chronic hep-
atitis C virus infection. It has terminal half life of about 4–5 h.
IFN-a26 loaded biodegradable PLGA microparticles were
prepared using a w/o/w double emulsion solvent evaporation
method Zhang et al., 2008a,b. The prepared microparticles
were spherical in shape with smooth surface. In vitro release
study showed 63–84% IFN-a26 released in 30 days. In vivo
study was conducted in rhesus monkeys by injecting intramus-
cularly with either commercial IFN-a26 lyophilized powder or
IFN-a26 loaded PLGA microparticles. In vivo study revealed
that the pharmacokinetic-pharmacodynamic properties be-
tween the IFN-a26 microparticles and IFN-a26 lyophilized
powder were signiﬁcantly different.
5.2.13. Glial cell-line derived neurotrophic factor (GDNF)
GDNF is a potent neurotrophic factor for dopaminergic neu-
rons widely used for treating Parkinson’s disease. GDNF
loaded PLGA microparticles were prepared using w/o/w dou-
ble emulsion method (Garbayo et al., 2008). The preparedmicroparticles showed a mean diameter between 8 and 30 lm
and drug entrapment efﬁciency ranged from 50% to 100%.
Microparticles prepared using PLGA RG503H released 67%
of the total protein content within 40 days.
5.2.14. Exenatide
Exenatide is a biopharmaceutical used for the treatment of dia-
betes mellitus type II. It has a half life of about 2.45 h. Its usual
dose is 5 lg subcutaneously twice daily. Acetylated pullen
microparticles were designed using w/o/w double emulsion
method for delivery of type II diabetic drug (exenatide) (Yang
et al., 2009). The prepared microparticles showed 68–90%
encapsulation efﬁciency. The release of exenatide from the
microparticles evidenced a sustained release proﬁle for 21 days.
Similarly, exenatide loaded PLGA microparticles were pre-
pared using a w/o/w double emulsion solvent evaporation
method (Liu et al., 2010). In vivo study in diabetic mice re-
vealed that exenatide microparticles have a signiﬁcant hypo-
glycemic activity within one month and its controlling of
plasma glucose was similar to that of exenatide solution in-
jected twice daily with identical exenatide amount.
5.2.15. Glucagon like peptide-1 (GLP-1)
GLP-1 is a gut hormone widely used for the treatment of type-
II diabetes mellitus. GLP-1 loaded PLGA microparticles were
prepared by w/o/o double emulsion solvent extraction method
(Yin et al., 2008). GLP-1 was micronized or complexed with
zinc, which was mixed with PLGA solution in acetonitrile.
Mixture was dropped in cottonseed oil containing lecithin.
GLP-1 zinc complexation signiﬁcantly reduced initial burst re-
lease from 37.2% to 7.5%. The optimized formulation
achieved controlled release in vivo for 28 days and exhibit sus-
tained long term pharmacological efﬁcacy to decrease blood
glucose level in diabetic mice.
5.2.16. Bovine hemoglobin
Bovine hemoglobin is the bovine blood obtained from hemo-
globin. It acts as an oxygen transporter. Qiu et al. (2004) pre-
pared bovine hemoglobin loaded PELA microparticles using a
w/o/w double emulsion solvent diffusion process. They inves-
tigated the inﬂuence of wall polymer and preparation process
on the particle size and encapsulation of microparticles. The
prepared microparticles with PELA copolymer containing
MPEG 2000 block showed encapsulation efﬁciency to 90%
and the particle size range between 3 and 5 lm. Moreover,
the encapsulation efﬁciency and particle size increased with
the concentration of PELA. Other preparation process that
inﬂuenced the encapsulation efﬁciency and particle size of
microparticles is concentration of NaCl in outer aqueous solu-
tion, concentration of stabilizer in outer aqueous solution, and
primary emulsion stirring rate.
5.2.17. Basic ﬁbroblast growth factor (bFGF)
Basic ﬁbroblast growth factor participates in the process of
wound healing, tissue repair, proliferation, and differentiation
of immature neural cells. It has mitogenic and angiogenic
properties and is used to treat the inﬂammatory bowel disease.
Shen et al. (2008) prepared bFGF loaded PLGA microparti-
cles using a double emulsion method. They also studied the
bioactivities of bFGF after release from microparticles on
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prepared microparticles were good. The in vitro release rate
of bFGF from microparticles was 72.47% in 11 days. The
in vitro cellular study revealed that the prepared microparticles
preserved the bioactivities of bFGF effectively and promote
the proliferation of Schwann cells in a long period because
of the controlled release of bFGF from the microparticles.
5.2.18. Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor is a signal protein produced
by cells that stimulate vasculogenesis and angiogenesis. It re-
stores the oxygen supply to tissue when blood circulation is
inadequate. It is used in the treatment of breast cancer, and
in rheumatoid arthritis. VEGF loaded PLGA microparticles
were prepared using a modiﬁed w/o/w double emulsion solvent
evaporation technique (Karal-Ylmaz et al., 2011). The pre-
pared microparticles were spherical in shape with diameters
of 10–60 lm and the encapsulation efﬁciency was between
46% and 60%. The microparticles containing 5 lg VEGF
per 500 mg starting polymer showed an initial burst release fol-
lowed by a higher steady-state release until 14 days.
5.2.19. Human immunoglobulin G (IgG)
Human immunoglobulin G is an antibody that constitutes
75% of serum immunoglobulin in humans. It provides protec-
tion to the fetus in uteri. Wang and his coworkers (Wang et al.,
2004) studied the stabilizing effects of various excipients during
the period of protein atomization using spray freeze drying
and subsequent encapsulation into PLGA microparticles using
a s/o/w double emulsion method. It was observed that ultra-
sonication did not change the primary structure of IgG signif-
icantly. However, subsequent double emulsion solvent
evaporation process denatured nearly 80% of the total amount
of IgG. Both mannitol and trehalose could stabilize IgG dur-
ing spray freeze-drying with over 90% retention of its molecu-
lar integrity and immunoactivity.
5.2.20. SPf66 malarial antigen
SPf66 malarial antigen is a synthetic peptide vaccine contain-
ing antigens obtained from the blood at sporozoite stage of
malaria infection. It is the ﬁrst malaria vaccine which is used
to prevent malaria. Igartua et al. (2008) investigated the effects
of gamma-irradiation on biopharmaceutical properties of
PLGA microparticles loaded with SPf66 malarial antigen.
The microparticles were prepared by a w/o/w double emulsion
solvent extraction method. First emulsion was formed by son-
ication and second emulsion was prepared by homogenization
in 8% PVA aqueous solution. Two percent isopropanol in
water was used to extract solvent. The in vitro results revealed
that the gamma irradiation exposure had no apparent effect on
SPf66 integrity and formulation properties such as morphol-
ogy, size and peptide loading. Moreover, SPf66 malarial anti-
gen retained in vivo activity up to week 27.
6. Conclusion
Microparticles made by the double emulsion technique are
excellent reservoirs for the encapsulation of a variety of
pharmaceutical and biopharmaceutical compounds. The
physico-chemical properties of microparticles and its drugrelease characteristics are dependent on many factors like drug
solubility, polymer composition and molecular weight, poly-
mer to core ratio, polymer crystallinity, and rate of solvent
evaporation and method of manufacture. Since last decade
there has been a great deal of research focused on the con-
trolled delivery of protein and peptide drug. Generally, the
w/o/w double emulsion method has been extensively used for
the encapsulation of protein and peptides. However, proteins
and peptides are susceptible to denaturation, degradation
and conformational changes during manufacturing w/o/w
double emulsion method which may render them inactive.
While by use of s/o/w, w/o/o, and s/o/o double emulsion meth-
od the problems associated with w/o/w double emulsion meth-
od could be avoided and stability of protein and peptide drugs
loaded microparticles can be improved. Much progress has
been made in recent years for the preparation of microparticles
by double emulsion technique but more is needed. Thus,
further development in the technology is still necessary for
producing larger amounts of microparticles that are safe,
economic, robust and well-controlled.
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